{"id":20090,"date":"2022-12-09T15:09:43","date_gmt":"2022-12-09T09:39:43","guid":{"rendered":"https:\/\/www.delveinsight.com\/blog\/?p=20090"},"modified":"2023-04-17T16:50:42","modified_gmt":"2023-04-17T11:20:42","slug":"ash-annual-meeting-dlbcl-abstracts-and-breakthroughs","status":"publish","type":"post","link":"https:\/\/www.delveinsight.com\/blog\/ash-annual-meeting-dlbcl-abstracts-and-breakthroughs","title":{"rendered":"ASH 2022 Annual Meeting &#8211; Insights Into Major Diffuse Large B-cell Lymphoma (DLBCL) Abstract and Breakthroughs"},"content":{"rendered":"\n<p>Blood cancers have seen tremendous advancements in the past few years owing to the dedication of the researchers who are putting their endless efforts just to bring innovation into the lives of suffering patients. These experiments and their upshots are always brought to us through various platforms, the <strong>American Society of Hematology (ASH)<\/strong> being one of them.<\/p>\n\n\n\n<p><strong>The 64th ASH Annual Meeting and Exposition <\/strong>is a four-day premier event in malignant and non-malignant hematology, <strong>scheduled to start on December 10, 2022<\/strong>. Like every year, the ASH conference shared new abstracts from a robust portfolio and pipeline of advanced therapeutic platforms in cancer and other blood disorders, highlighting the impact of our bold science in research. On this note, Delveinsight has listed a few <strong><a href=\"https:\/\/www.delveinsight.com\/report-store\/diffuse-large-b-cell-lymphoma-market\">major abstracts for diffuse large B-cell lymphoma (DLBCL)<\/a>.<\/strong><\/p>\n\n\n\n<p><strong>The key abstracts have been summarized in the table below:<\/strong><\/p>\n\n\n\n<div>\n<table style=\"border:none; border-collapse:collapse\" width=\"557\">\n\t<colgroup>\n\t\t<col width=\"96\">\n\t\t<col width=\"54\">\n\t\t<col width=\"118\">\n\t\t<col width=\"84\">\n\t\t<col width=\"94\">\n\t\t<col width=\"111\">\n\t<\/colgroup>\n\t<tbody>\n\t\t<tr>\n\t\t\t<td style=\"border-bottom:1px solid #000000; vertical-align:middle; background-color:#cc223d; padding:0px 7px 0px 7px; border-top:1px solid #000000; border-right:1px solid #000000; border-left:1px solid #000000; width:96px\">\n\t\t\t<p style=\"line-height:1.2; text-align:justify\"><span style=\"overflow:hidden\"><span style=\"overflow-wrap:break-word\"><span style=\"font-size:10pt; font-variant:normal; white-space:pre-wrap\"><span style=\"font-family:Cambria,serif\"><span style=\"color:#ffffff\"><span style=\"font-weight:700\"><span style=\"font-style:normal\"><span style=\"text-decoration:none\">Drug regimen<\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/p>\n\t\t\t<\/td>\n\t\t\t<td style=\"border-bottom:1px solid #000000; vertical-align:middle; background-color:#cc223d; padding:0px 7px 0px 7px; border-top:1px solid #000000; border-right:1px solid #000000; border-left:1px solid #000000; width:54px\">\n\t\t\t<p style=\"line-height:1.2; text-align:justify\"><span style=\"overflow:hidden\"><span style=\"overflow-wrap:break-word\"><span style=\"font-size:10pt; font-variant:normal; white-space:pre-wrap\"><span style=\"font-family:Cambria,serif\"><span style=\"color:#ffffff\"><span style=\"font-weight:700\"><span style=\"font-style:normal\"><span style=\"text-decoration:none\">Abstract ID<\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/p>\n\t\t\t<\/td>\n\t\t\t<td style=\"border-bottom:1px solid #000000; vertical-align:middle; background-color:#cc223d; padding:0px 7px 0px 7px; border-top:1px solid #000000; border-right:1px solid #000000; border-left:1px solid #000000; width:118px\">\n\t\t\t<p style=\"line-height:1.2; text-align:justify\"><span style=\"overflow:hidden\"><span style=\"overflow-wrap:break-word\"><span style=\"font-size:10pt; font-variant:normal; white-space:pre-wrap\"><span style=\"font-family:Cambria,serif\"><span style=\"color:#ffffff\"><span style=\"font-weight:700\"><span style=\"font-style:normal\"><span style=\"text-decoration:none\">Abstract Title<\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/p>\n\t\t\t<\/td>\n\t\t\t<td style=\"border-bottom:1px solid #000000; vertical-align:middle; background-color:#cc223d; padding:0px 7px 0px 7px; border-top:1px solid #000000; border-right:1px solid #000000; border-left:1px solid #000000; width:84px\">\n\t\t\t<p style=\"line-height:1.2; text-align:justify\"><span style=\"overflow:hidden\"><span style=\"overflow-wrap:break-word\"><span style=\"font-size:10pt; font-variant:normal; white-space:pre-wrap\"><span style=\"font-family:Cambria,serif\"><span style=\"color:#ffffff\"><span style=\"font-weight:700\"><span style=\"font-style:normal\"><span style=\"text-decoration:none\">Trial ID<\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/p>\n\t\t\t<\/td>\n\t\t\t<td style=\"border-bottom:1px solid #000000; vertical-align:middle; background-color:#cc223d; padding:0px 7px 0px 7px; border-top:1px solid #000000; border-right:1px solid #000000; border-left:1px solid #000000; width:94px\">\n\t\t\t<p style=\"line-height:1.2; text-align:justify\"><span style=\"overflow:hidden\"><span style=\"overflow-wrap:break-word\"><span style=\"font-size:10pt; font-variant:normal; white-space:pre-wrap\"><span style=\"font-family:Cambria,serif\"><span style=\"color:#ffffff\"><span style=\"font-weight:700\"><span style=\"font-style:normal\"><span style=\"text-decoration:none\">Company<\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/p>\n\t\t\t<\/td>\n\t\t\t<td style=\"border-bottom:1px solid #000000; vertical-align:middle; background-color:#cc223d; padding:0px 7px 0px 7px; border-top:1px solid #000000; border-right:1px solid #000000; border-left:1px solid #000000; width:111px\">\n\t\t\t<p style=\"line-height:1.2; text-align:justify\"><span style=\"overflow:hidden\"><span style=\"overflow-wrap:break-word\"><span style=\"font-size:10pt; font-variant:normal; white-space:pre-wrap\"><span style=\"font-family:Cambria,serif\"><span style=\"color:#ffffff\"><span style=\"font-weight:700\"><span style=\"font-style:normal\"><span style=\"text-decoration:none\">Class<\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/p>\n\t\t\t<\/td>\n\t\t<\/tr>\n\t\t<tr>\n\t\t\t<td style=\"border-bottom:1px solid #000000; vertical-align:middle; background-color:#f2f2f2; padding:0px 7px 0px 7px; border-top:1px solid #000000; border-right:1px solid #000000; border-left:1px solid #000000; width:96px\">\n\t\t\t<p style=\"line-height:1.2\"><span style=\"overflow:hidden\"><span style=\"overflow-wrap:break-word\"><span style=\"font-size:9pt; font-variant:normal; white-space:pre-wrap\"><span style=\"font-family:Cambria,serif\"><span style=\"color:#000000\"><span style=\"font-weight:700\"><span style=\"font-style:normal\"><span style=\"text-decoration:none\">Tafasitamab + Lenalidomide + R-CHOP<\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/p>\n\t\t\t<\/td>\n\t\t\t<td style=\"border-bottom:1px solid #000000; vertical-align:middle; background-color:#f2f2f2; padding:0px 7px 0px 7px; border-top:1px solid #000000; border-right:1px solid #000000; border-left:1px solid #000000; width:54px\">\n\t\t\t<p style=\"line-height:1.2\"><span style=\"overflow:hidden\"><span style=\"overflow-wrap:break-word\"><span style=\"font-size:9pt; font-variant:normal; white-space:pre-wrap\"><span style=\"font-family:Cambria,serif\"><span style=\"color:#000000\"><span style=\"font-weight:400\"><span style=\"font-style:normal\"><span style=\"text-decoration:none\">2947<\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/p>\n\t\t\t<\/td>\n\t\t\t<td style=\"border-bottom:1px solid #000000; vertical-align:middle; background-color:#f2f2f2; padding:0px 7px 0px 7px; border-top:1px solid #000000; border-right:1px solid #000000; border-left:1px solid #000000; width:118px\">\n\t\t\t<p style=\"line-height:1.2\"><span style=\"overflow:hidden\"><span style=\"overflow-wrap:break-word\"><span style=\"font-size:9pt; font-variant:normal; white-space:pre-wrap\"><span style=\"font-family:Cambria,serif\"><span style=\"color:#000000\"><span style=\"font-weight:400\"><span style=\"font-style:normal\"><span style=\"text-decoration:none\">Frontmind: A Phase III, Multicenter, Randomized, Double-Blind Study of Tafasitamab + Lenalidomide + R-CHOP Versus R-CHOP Alone for Newly Diagnosed High-Intermediate and High-Risk Diffuse Large B-Cell Lymphoma<\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/p>\n\t\t\t<\/td>\n\t\t\t<td style=\"border-bottom:1px solid #000000; vertical-align:middle; background-color:#f2f2f2; padding:0px 7px 0px 7px; border-top:1px solid #000000; border-right:1px solid #000000; border-left:1px solid #000000; width:84px\">\n\t\t\t<p style=\"line-height:1.2\"><span style=\"overflow:hidden\"><span style=\"overflow-wrap:break-word\"><span style=\"font-size:9pt; font-variant:normal; white-space:pre-wrap\"><span style=\"font-family:Cambria,serif\"><span style=\"color:#000000\"><span style=\"font-weight:400\"><span style=\"font-style:normal\"><span style=\"text-decoration:none\">NCT04824092<\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/p>\n\n\t\t\t<p style=\"line-height:1.2\"><span style=\"overflow:hidden\"><span style=\"overflow-wrap:break-word\"><span style=\"font-size:9pt; font-variant:normal; white-space:pre-wrap\"><span style=\"font-family:Cambria,serif\"><span style=\"color:#000000\"><span style=\"font-weight:400\"><span style=\"font-style:normal\"><span style=\"text-decoration:none\">(frontMIND)<\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/p>\n\t\t\t<\/td>\n\t\t\t<td style=\"border-bottom:1px solid #000000; vertical-align:middle; background-color:#f2f2f2; padding:0px 7px 0px 7px; border-top:1px solid #000000; border-right:1px solid #000000; border-left:1px solid #000000; width:94px\">\n\t\t\t<p style=\"line-height:1.2\"><span style=\"overflow:hidden\"><span style=\"overflow-wrap:break-word\"><span style=\"font-size:9pt; font-variant:normal; white-space:pre-wrap\"><span style=\"font-family:Cambria,serif\"><span style=\"color:#000000\"><span style=\"font-weight:400\"><span style=\"font-style:normal\"><span style=\"text-decoration:none\">MorphoSys AG<\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/p>\n\t\t\t<\/td>\n\t\t\t<td style=\"border-bottom:1px solid #000000; vertical-align:middle; background-color:#f2f2f2; padding:0px 7px 0px 7px; border-top:1px solid #000000; border-right:1px solid #000000; border-left:1px solid #000000; width:111px\">\n\t\t\t<p style=\"line-height:1.2\"><span style=\"overflow:hidden\"><span style=\"overflow-wrap:break-word\"><span style=\"font-size:9pt; font-variant:normal; white-space:pre-wrap\"><span style=\"font-family:Cambria,serif\"><span style=\"color:#000000\"><span style=\"font-weight:400\"><span style=\"font-style:normal\"><span style=\"text-decoration:none\">CD19-directed monoclonal antibody<\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/p>\n\t\t\t<\/td>\n\t\t<\/tr>\n\t\t<tr>\n\t\t\t<td style=\"border-bottom:1px solid #000000; vertical-align:middle; background-color:#ffffff; padding:0px 7px 0px 7px; border-top:1px solid #000000; border-right:1px solid #000000; border-left:1px solid #000000; width:96px\">\n\t\t\t<p style=\"line-height:1.2\"><span style=\"overflow:hidden\"><span style=\"overflow-wrap:break-word\"><span style=\"font-size:9pt; font-variant:normal; white-space:pre-wrap\"><span style=\"font-family:Cambria,serif\"><span style=\"color:#000000\"><span style=\"font-weight:700\"><span style=\"font-style:normal\"><span style=\"text-decoration:none\">Odronextamab<\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/p>\n\t\t\t<\/td>\n\t\t\t<td style=\"border-bottom:1px solid #000000; vertical-align:middle; background-color:#ffffff; padding:0px 7px 0px 7px; border-top:1px solid #000000; border-right:1px solid #000000; border-left:1px solid #000000; width:54px\">\n\t\t\t<p style=\"line-height:1.2\"><span style=\"overflow:hidden\"><span style=\"overflow-wrap:break-word\"><span style=\"font-size:9pt; font-variant:normal; white-space:pre-wrap\"><span style=\"font-family:Cambria,serif\"><span style=\"color:#000000\"><span style=\"font-weight:400\"><span style=\"font-style:normal\"><span style=\"text-decoration:none\">444<\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/p>\n\t\t\t<\/td>\n\t\t\t<td style=\"border-bottom:1px solid #000000; vertical-align:middle; background-color:#ffffff; padding:0px 7px 0px 7px; border-top:1px solid #000000; border-right:1px solid #000000; border-left:1px solid #000000; width:118px\">\n\t\t\t<p style=\"line-height:1.2\"><span style=\"overflow:hidden\"><span style=\"overflow-wrap:break-word\"><span style=\"font-size:9pt; font-variant:normal; white-space:pre-wrap\"><span style=\"font-family:Cambria,serif\"><span style=\"color:#000000\"><span style=\"font-weight:400\"><span style=\"font-style:normal\"><span style=\"text-decoration:none\">Odronextamab in Patients with Relapsed\/Refractory (R\/R) Diffuse Large B-Cell Lymphoma (DLBCL): Results from a Prespecified Analysis of the Pivotal Phase II Study ELM-2<\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/p>\n\t\t\t<\/td>\n\t\t\t<td style=\"border-bottom:1px solid #000000; vertical-align:middle; background-color:#ffffff; padding:0px 7px 0px 7px; border-top:1px solid #000000; border-right:1px solid #000000; border-left:1px solid #000000; width:84px\">\n\t\t\t<p style=\"line-height:1.2\"><span style=\"overflow:hidden\"><span style=\"overflow-wrap:break-word\"><span style=\"font-size:9pt; font-variant:normal; white-space:pre-wrap\"><span style=\"font-family:Cambria,serif\"><span style=\"color:#000000\"><span style=\"font-weight:400\"><span style=\"font-style:normal\"><span style=\"text-decoration:none\">NCT03888105<\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/p>\n\n\t\t\t<p style=\"line-height:1.2\"><span style=\"overflow:hidden\"><span style=\"overflow-wrap:break-word\"><span style=\"font-size:9pt; font-variant:normal; white-space:pre-wrap\"><span style=\"font-family:Cambria,serif\"><span style=\"color:#000000\"><span style=\"font-weight:400\"><span style=\"font-style:normal\"><span style=\"text-decoration:none\">(ELM-2)<\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/p>\n\t\t\t<\/td>\n\t\t\t<td style=\"border-bottom:1px solid #000000; vertical-align:middle; background-color:#ffffff; padding:0px 7px 0px 7px; border-top:1px solid #000000; border-right:1px solid #000000; border-left:1px solid #000000; width:94px\">\n\t\t\t<p style=\"line-height:1.2\"><span style=\"overflow:hidden\"><span style=\"overflow-wrap:break-word\"><span style=\"font-size:9pt; font-variant:normal; white-space:pre-wrap\"><span style=\"font-family:Cambria,serif\"><span style=\"color:#000000\"><span style=\"font-weight:400\"><span style=\"font-style:normal\"><span style=\"text-decoration:none\">Regeneron Pharmaceuticals<\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/p>\n\t\t\t<\/td>\n\t\t\t<td style=\"border-bottom:1px solid #000000; vertical-align:middle; background-color:#ffffff; padding:0px 7px 0px 7px; border-top:1px solid #000000; border-right:1px solid #000000; border-left:1px solid #000000; width:111px\">\n\t\t\t<p style=\"line-height:1.2\"><span style=\"overflow:hidden\"><span style=\"overflow-wrap:break-word\"><span style=\"font-size:9pt; font-variant:normal; white-space:pre-wrap\"><span style=\"font-family:Cambria,serif\"><span style=\"color:#000000\"><span style=\"font-weight:400\"><span style=\"font-style:normal\"><span style=\"text-decoration:none\">Bispecific antibody<\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/p>\n\t\t\t<\/td>\n\t\t<\/tr>\n\t\t<tr>\n\t\t\t<td style=\"border-bottom:1px solid #000000; vertical-align:middle; background-color:#f2f2f2; padding:0px 7px 0px 7px; border-top:1px solid #000000; border-right:1px solid #000000; border-left:1px solid #000000; width:96px\">\n\t\t\t<p style=\"line-height:1.2; margin-top:16px\"><span style=\"overflow:hidden\"><span style=\"overflow-wrap:break-word\"><span style=\"font-size:9pt; font-variant:normal; white-space:pre-wrap\"><span style=\"font-family:Cambria,serif\"><span style=\"color:#000000\"><span style=\"font-weight:700\"><span style=\"font-style:normal\"><span style=\"text-decoration:none\">Loncastuximab Tesirine + Rituximab<\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/p>\n\t\t\t<\/td>\n\t\t\t<td style=\"border-bottom:1px solid #000000; vertical-align:middle; background-color:#f2f2f2; padding:0px 7px 0px 7px; border-top:1px solid #000000; border-right:1px solid #000000; border-left:1px solid #000000; width:54px\">\n\t\t\t<p style=\"line-height:1.2; margin-top:16px\"><span style=\"overflow:hidden\"><span style=\"overflow-wrap:break-word\"><span style=\"font-size:9pt; font-variant:normal; white-space:pre-wrap\"><span style=\"font-family:Cambria,serif\"><span style=\"color:#000000\"><span style=\"font-weight:400\"><span style=\"font-style:normal\"><span style=\"text-decoration:none\">2955<\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/p>\n\t\t\t<\/td>\n\t\t\t<td style=\"border-bottom:1px solid #000000; vertical-align:middle; background-color:#f2f2f2; padding:0px 7px 0px 7px; border-top:1px solid #000000; border-right:1px solid #000000; border-left:1px solid #000000; width:118px\">\n\t\t\t<p style=\"line-height:1.2; margin-top:16px\"><span style=\"overflow:hidden\"><span style=\"overflow-wrap:break-word\"><span style=\"font-size:9pt; font-variant:normal; white-space:pre-wrap\"><span style=\"font-family:Cambria,serif\"><span style=\"color:#000000\"><span style=\"font-weight:400\"><span style=\"font-style:normal\"><span style=\"text-decoration:none\">A Phase II, Open-Label Study of Loncastuximab Tesirine in Combination with Rituximab (Lonca-R) in Previously Untreated Unfit\/Frail Patients with Diffuse Large B-Cell Lymphoma (DLBCL) (LOTIS-9)<\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/p>\n\t\t\t<\/td>\n\t\t\t<td style=\"border-bottom:1px solid #000000; vertical-align:middle; background-color:#f2f2f2; padding:0px 7px 0px 7px; border-top:1px solid #000000; border-right:1px solid #000000; border-left:1px solid #000000; width:84px\">\n\t\t\t<p style=\"line-height:1.2; margin-top:16px\"><span style=\"overflow:hidden\"><span style=\"overflow-wrap:break-word\"><span style=\"font-size:9pt; font-variant:normal; white-space:pre-wrap\"><span style=\"font-family:Cambria,serif\"><span style=\"color:#000000\"><span style=\"font-weight:400\"><span style=\"font-style:normal\"><span style=\"text-decoration:none\">NCT05144009<\/span><\/span><\/span><\/span><\/span><\/span><span style=\"font-size:12pt; font-variant:normal; white-space:pre-wrap\"><span style=\"font-family:Cambria,serif\"><span style=\"color:#000000\"><span style=\"font-weight:400\"><span style=\"font-style:normal\"><span style=\"text-decoration:none\"> <\/span><\/span><\/span><\/span><\/span><\/span><span style=\"font-size:9pt; font-variant:normal; white-space:pre-wrap\"><span style=\"font-family:Cambria,serif\"><span style=\"color:#000000\"><span style=\"font-weight:400\"><span style=\"font-style:normal\"><span style=\"text-decoration:none\">(LOTIS-9)<\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/p>\n\t\t\t<\/td>\n\t\t\t<td style=\"border-bottom:1px solid #000000; vertical-align:middle; background-color:#f2f2f2; padding:0px 7px 0px 7px; border-top:1px solid #000000; border-right:1px solid #000000; border-left:1px solid #000000; width:94px\">\n\t\t\t<p style=\"line-height:1.2; margin-top:16px\"><span style=\"overflow:hidden\"><span style=\"overflow-wrap:break-word\"><span style=\"font-size:9pt; font-variant:normal; white-space:pre-wrap\"><span style=\"font-family:Cambria,serif\"><span style=\"color:#000000\"><span style=\"font-weight:400\"><span style=\"font-style:normal\"><span style=\"text-decoration:none\">ADC Therapeutics<\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/p>\n\t\t\t<\/td>\n\t\t\t<td style=\"border-bottom:1px solid #000000; vertical-align:middle; background-color:#f2f2f2; padding:0px 7px 0px 7px; border-top:1px solid #000000; border-right:1px solid #000000; border-left:1px solid #000000; width:111px\">\n\t\t\t<p style=\"line-height:1.2; margin-top:16px\"><span style=\"overflow:hidden\"><span style=\"overflow-wrap:break-word\"><span style=\"font-size:9pt; font-variant:normal; white-space:pre-wrap\"><span style=\"font-family:Cambria,serif\"><span style=\"color:#000000\"><span style=\"font-weight:400\"><span style=\"font-style:normal\"><span style=\"text-decoration:none\">Antibody Drug Conjugate (ADC)<\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/p>\n\t\t\t<\/td>\n\t\t<\/tr>\n\t\t<tr>\n\t\t\t<td style=\"border-bottom:1px solid #000000; vertical-align:middle; background-color:#ffffff; padding:0px 7px 0px 7px; border-top:1px solid #000000; border-right:1px solid #000000; border-left:1px solid #000000; width:96px\">\n\t\t\t<p style=\"line-height:1.2\"><span style=\"overflow:hidden\"><span style=\"overflow-wrap:break-word\"><span style=\"font-size:9pt; font-variant:normal; white-space:pre-wrap\"><span style=\"font-family:Cambria,serif\"><span style=\"color:#000000\"><span style=\"font-weight:700\"><span style=\"font-style:normal\"><span style=\"text-decoration:none\">Epcoritamab + R-DHAX\/C<\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/p>\n\t\t\t<\/td>\n\t\t\t<td style=\"border-bottom:1px solid #000000; vertical-align:middle; background-color:#ffffff; padding:0px 7px 0px 7px; border-top:1px solid #000000; border-right:1px solid #000000; border-left:1px solid #000000; width:54px\">\n\t\t\t<p style=\"line-height:1.2\"><span style=\"overflow:hidden\"><span style=\"overflow-wrap:break-word\"><span style=\"font-size:9pt; font-variant:normal; white-space:pre-wrap\"><span style=\"font-family:Cambria,serif\"><span style=\"color:#000000\"><span style=\"font-weight:400\"><span style=\"font-style:normal\"><span style=\"text-decoration:none\">443<\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/p>\n\t\t\t<\/td>\n\t\t\t<td style=\"border-bottom:1px solid #000000; vertical-align:middle; background-color:#ffffff; padding:0px 7px 0px 7px; border-top:1px solid #000000; border-right:1px solid #000000; border-left:1px solid #000000; width:118px\">\n\t\t\t<p style=\"line-height:1.2\"><span style=\"overflow:hidden\"><span style=\"overflow-wrap:break-word\"><span style=\"font-size:9pt; font-variant:normal; white-space:pre-wrap\"><span style=\"font-family:Cambria,serif\"><span style=\"color:#000000\"><span style=\"font-weight:400\"><span style=\"font-style:normal\"><span style=\"text-decoration:none\">Subcutaneous Epcoritamab + R-Dhax\/C in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma Eligible for Autologous Stem Cell Transplant: Updated Phase I\/II Results<\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/p>\n\t\t\t<\/td>\n\t\t\t<td style=\"border-bottom:1px solid #000000; vertical-align:middle; background-color:#ffffff; padding:0px 7px 0px 7px; border-top:1px solid #000000; border-right:1px solid #000000; border-left:1px solid #000000; width:84px\">\n\t\t\t<p style=\"line-height:1.2\"><span style=\"overflow:hidden\"><span style=\"overflow-wrap:break-word\"><span style=\"font-size:9pt; font-variant:normal; white-space:pre-wrap\"><span style=\"font-family:Cambria,serif\"><span style=\"color:#000000\"><span style=\"font-weight:400\"><span style=\"font-style:normal\"><span style=\"text-decoration:none\">NCT04663347<\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/p>\n\n\t\t\t<p style=\"line-height:1.2\"><span style=\"overflow:hidden\"><span style=\"overflow-wrap:break-word\"><span style=\"font-size:9pt; font-variant:normal; white-space:pre-wrap\"><span style=\"font-family:Cambria,serif\"><span style=\"color:#000000\"><span style=\"font-weight:400\"><span style=\"font-style:normal\"><span style=\"text-decoration:none\">(EPCORE NHL-2)<\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/p>\n\t\t\t<\/td>\n\t\t\t<td style=\"border-bottom:1px solid #000000; vertical-align:middle; background-color:#ffffff; padding:0px 7px 0px 7px; border-top:1px solid #000000; border-right:1px solid #000000; border-left:1px solid #000000; width:94px\">\n\t\t\t<p style=\"line-height:1.2\"><span style=\"overflow:hidden\"><span style=\"overflow-wrap:break-word\"><span style=\"font-size:9pt; font-variant:normal; white-space:pre-wrap\"><span style=\"font-family:Cambria,serif\"><span style=\"color:#000000\"><span style=\"font-weight:400\"><span style=\"font-style:normal\"><span style=\"text-decoration:none\">Genmab\/AbbVie<\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/p>\n\t\t\t<\/td>\n\t\t\t<td style=\"border-bottom:1px solid #000000; vertical-align:middle; background-color:#ffffff; padding:0px 7px 0px 7px; border-top:1px solid #000000; border-right:1px solid #000000; border-left:1px solid #000000; width:111px\">\n\t\t\t<p style=\"line-height:1.2\"><span style=\"overflow:hidden\"><span style=\"overflow-wrap:break-word\"><span style=\"font-size:9pt; font-variant:normal; white-space:pre-wrap\"><span style=\"font-family:Cambria,serif\"><span style=\"color:#000000\"><span style=\"font-weight:400\"><span style=\"font-style:normal\"><span style=\"text-decoration:none\">Bispecific antibody<\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/p>\n\t\t\t<\/td>\n\t\t<\/tr>\n\t\t<tr>\n\t\t\t<td style=\"border-bottom:1px solid #000000; vertical-align:middle; background-color:#f2f2f2; padding:0px 7px 0px 7px; border-top:1px solid #000000; border-right:1px solid #000000; border-left:1px solid #000000; width:96px\">\n\t\t\t<p style=\"line-height:1.2\"><span style=\"overflow:hidden\"><span style=\"overflow-wrap:break-word\"><span style=\"font-size:9pt; font-variant:normal; white-space:pre-wrap\"><span style=\"font-family:Cambria,serif\"><span style=\"color:#000000\"><span style=\"font-weight:700\"><span style=\"font-style:normal\"><span style=\"text-decoration:none\">Mosunetuzumab<\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/p>\n\t\t\t<\/td>\n\t\t\t<td style=\"border-bottom:1px solid #000000; vertical-align:middle; background-color:#f2f2f2; padding:0px 7px 0px 7px; border-top:1px solid #000000; border-right:1px solid #000000; border-left:1px solid #000000; width:54px\">\n\t\t\t<p style=\"line-height:1.2\"><span style=\"overflow:hidden\"><span style=\"overflow-wrap:break-word\"><span style=\"font-size:9pt; font-variant:normal; white-space:pre-wrap\"><span style=\"font-family:Cambria,serif\"><span style=\"color:#000000\"><span style=\"font-weight:400\"><span style=\"font-style:normal\"><span style=\"text-decoration:none\">738<\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/p>\n\t\t\t<\/td>\n\t\t\t<td style=\"border-bottom:1px solid #000000; vertical-align:middle; background-color:#f2f2f2; padding:0px 7px 0px 7px; border-top:1px solid #000000; border-right:1px solid #000000; border-left:1px solid #000000; width:118px\">\n\t\t\t<p style=\"line-height:1.2\"><span style=\"overflow:hidden\"><span style=\"overflow-wrap:break-word\"><span style=\"font-size:9pt; font-variant:normal; white-space:pre-wrap\"><span style=\"font-family:Cambria,serif\"><span style=\"color:#000000\"><span style=\"font-weight:400\"><span style=\"font-style:normal\"><span style=\"text-decoration:none\">Mosunetuzumab Monotherapy Continues to Demonstrate Promising Efficacy and Durable Complete Responses in Elderly\/Unfit Patients with Previously Untreated Diffuse Large B-Cell Lymphoma<\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/p>\n\t\t\t<\/td>\n\t\t\t<td style=\"border-bottom:1px solid #000000; vertical-align:middle; background-color:#f2f2f2; padding:0px 7px 0px 7px; border-top:1px solid #000000; border-right:1px solid #000000; border-left:1px solid #000000; width:84px\">\n\t\t\t<p style=\"line-height:1.2\"><span style=\"overflow:hidden\"><span style=\"overflow-wrap:break-word\"><span style=\"font-size:9pt; font-variant:normal; white-space:pre-wrap\"><span style=\"font-family:Cambria,serif\"><span style=\"color:#000000\"><span style=\"font-weight:400\"><span style=\"font-style:normal\"><span style=\"text-decoration:none\">NCT03677154<\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/p>\n\t\t\t<\/td>\n\t\t\t<td style=\"border-bottom:1px solid #000000; vertical-align:middle; background-color:#f2f2f2; padding:0px 7px 0px 7px; border-top:1px solid #000000; border-right:1px solid #000000; border-left:1px solid #000000; width:94px\">\n\t\t\t<p style=\"line-height:1.2\"><span style=\"overflow:hidden\"><span style=\"overflow-wrap:break-word\"><span style=\"font-size:9pt; font-variant:normal; white-space:pre-wrap\"><span style=\"font-family:Cambria,serif\"><span style=\"color:#000000\"><span style=\"font-weight:400\"><span style=\"font-style:normal\"><span style=\"text-decoration:none\">Roche<\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/p>\n\t\t\t<\/td>\n\t\t\t<td style=\"border-bottom:1px solid #000000; vertical-align:middle; background-color:#f2f2f2; padding:0px 7px 0px 7px; border-top:1px solid #000000; border-right:1px solid #000000; border-left:1px solid #000000; width:111px\">\n\t\t\t<p style=\"line-height:1.2\"><span style=\"overflow:hidden\"><span style=\"overflow-wrap:break-word\"><span style=\"font-size:9pt; font-variant:normal; white-space:pre-wrap\"><span style=\"font-family:Cambria,serif\"><span style=\"color:#000000\"><span style=\"font-weight:400\"><span style=\"font-style:normal\"><span style=\"text-decoration:none\">Bispecific antibody<\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/p>\n\t\t\t<\/td>\n\t\t<\/tr>\n\t\t<tr>\n\t\t\t<td style=\"border-bottom:1px solid #000000; vertical-align:middle; background-color:#ffffff; padding:0px 7px 0px 7px; border-top:1px solid #000000; border-right:1px solid #000000; border-left:1px solid #000000; width:96px\">\n\t\t\t<p style=\"line-height:1.2\"><span style=\"overflow:hidden\"><span style=\"overflow-wrap:break-word\"><span style=\"font-size:9pt; font-variant:normal; white-space:pre-wrap\"><span style=\"font-family:Cambria,serif\"><span style=\"color:#000000\"><span style=\"font-weight:700\"><span style=\"font-style:normal\"><span style=\"text-decoration:none\">Axicabtagene Ciloleucel&nbsp; + Lenzilumab<\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/p>\n\t\t\t<\/td>\n\t\t\t<td style=\"border-bottom:1px solid #000000; vertical-align:middle; background-color:#ffffff; padding:0px 7px 0px 7px; border-top:1px solid #000000; border-right:1px solid #000000; border-left:1px solid #000000; width:54px\">\n\t\t\t<p style=\"line-height:1.2\"><span style=\"overflow:hidden\"><span style=\"overflow-wrap:break-word\"><span style=\"font-size:9pt; font-variant:normal; white-space:pre-wrap\"><span style=\"font-family:Cambria,serif\"><span style=\"color:#000000\"><span style=\"font-weight:400\"><span style=\"font-style:normal\"><span style=\"text-decoration:none\">4635<\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/p>\n\t\t\t<\/td>\n\t\t\t<td style=\"border-bottom:1px solid #000000; vertical-align:middle; background-color:#ffffff; padding:0px 7px 0px 7px; border-top:1px solid #000000; border-right:1px solid #000000; border-left:1px solid #000000; width:118px\">\n\t\t\t<p style=\"line-height:1.2\"><span style=\"overflow:hidden\"><span style=\"overflow-wrap:break-word\"><span style=\"font-size:9pt; font-variant:normal; white-space:pre-wrap\"><span style=\"font-family:Cambria,serif\"><span style=\"color:#000000\"><span style=\"font-weight:400\"><span style=\"font-style:normal\"><span style=\"text-decoration:none\">ZUMA-19: A Phase I\/II Study of Axicabtagene Ciloleucel Plus Lenzilumab in Patients With Relapsed or Refractory Large B-Cell Lymphoma<\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/p>\n\t\t\t<\/td>\n\t\t\t<td style=\"border-bottom:1px solid #000000; vertical-align:middle; background-color:#ffffff; padding:0px 7px 0px 7px; border-top:1px solid #000000; border-right:1px solid #000000; border-left:1px solid #000000; width:84px\">\n\t\t\t<p style=\"line-height:1.2\"><span style=\"overflow:hidden\"><span style=\"overflow-wrap:break-word\"><span style=\"font-size:9pt; font-variant:normal; white-space:pre-wrap\"><span style=\"font-family:Cambria,serif\"><span style=\"color:#000000\"><span style=\"font-weight:400\"><span style=\"font-style:normal\"><span style=\"text-decoration:none\">NCT04314843<\/span><\/span><\/span><\/span><\/span><\/span><span style=\"font-size:12pt; font-variant:normal; white-space:pre-wrap\"><span style=\"font-family:Cambria,serif\"><span style=\"color:#000000\"><span style=\"font-weight:400\"><span style=\"font-style:normal\"><span style=\"text-decoration:none\"> <\/span><\/span><\/span><\/span><\/span><\/span><span style=\"font-size:9pt; font-variant:normal; white-space:pre-wrap\"><span style=\"font-family:Cambria,serif\"><span style=\"color:#000000\"><span style=\"font-weight:400\"><span style=\"font-style:normal\"><span style=\"text-decoration:none\">(ZUMA-19)<\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/p>\n\t\t\t<\/td>\n\t\t\t<td style=\"border-bottom:1px solid #000000; vertical-align:middle; background-color:#ffffff; padding:0px 7px 0px 7px; border-top:1px solid #000000; border-right:1px solid #000000; border-left:1px solid #000000; width:94px\">\n\t\t\t<p style=\"line-height:1.2\"><span style=\"overflow:hidden\"><span style=\"overflow-wrap:break-word\"><span style=\"font-size:9pt; font-variant:normal; white-space:pre-wrap\"><span style=\"font-family:Cambria,serif\"><span style=\"color:#000000\"><span style=\"font-weight:400\"><span style=\"font-style:normal\"><span style=\"text-decoration:none\">Gilead Sciences<\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/p>\n\t\t\t<\/td>\n\t\t\t<td style=\"border-bottom:1px solid #000000; vertical-align:middle; background-color:#ffffff; padding:0px 7px 0px 7px; border-top:1px solid #000000; border-right:1px solid #000000; border-left:1px solid #000000; width:111px\">\n\t\t\t<p style=\"line-height:1.2\"><span style=\"overflow:hidden\"><span style=\"overflow-wrap:break-word\"><span style=\"font-size:9pt; font-variant:normal; white-space:pre-wrap\"><span style=\"font-family:Cambria,serif\"><span style=\"color:#000000\"><span style=\"font-weight:400\"><span style=\"font-style:normal\"><span style=\"text-decoration:none\">CAR-T cell therapy<\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/p>\n\t\t\t<\/td>\n\t\t<\/tr>\n\t\t<tr>\n\t\t\t<td style=\"border-bottom:1px solid #000000; vertical-align:middle; background-color:#f2f2f2; padding:0px 7px 0px 7px; border-top:1px solid #000000; border-right:1px solid #000000; border-left:1px solid #000000; width:96px\">\n\t\t\t<p style=\"line-height:1.2\"><span style=\"overflow:hidden\"><span style=\"overflow-wrap:break-word\"><span style=\"font-size:9pt; font-variant:normal; white-space:pre-wrap\"><span style=\"font-family:Cambria,serif\"><span style=\"color:#000000\"><span style=\"font-weight:700\"><span style=\"font-style:normal\"><span style=\"text-decoration:none\">Iberdomide \u00b1<\/span><\/span><\/span><\/span><\/span><\/span><span style=\"font-size:12pt; font-variant:normal; white-space:pre-wrap\"><span style=\"font-family:Cambria,serif\"><span style=\"color:#000000\"><span style=\"font-weight:700\"><span style=\"font-style:normal\"><span style=\"text-decoration:none\"> <\/span><\/span><\/span><\/span><\/span><\/span><span style=\"font-size:9pt; font-variant:normal; white-space:pre-wrap\"><span style=\"font-family:Cambria,serif\"><span style=\"color:#000000\"><span style=\"font-weight:700\"><span style=\"font-style:normal\"><span style=\"text-decoration:none\">Anti-CD20<\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/p>\n\t\t\t<\/td>\n\t\t\t<td style=\"border-bottom:1px solid #000000; vertical-align:middle; background-color:#f2f2f2; padding:0px 7px 0px 7px; border-top:1px solid #000000; border-right:1px solid #000000; border-left:1px solid #000000; width:54px\">\n\t\t\t<p style=\"line-height:1.2\"><span style=\"overflow:hidden\"><span style=\"overflow-wrap:break-word\"><span style=\"font-size:9pt; font-variant:normal; white-space:pre-wrap\"><span style=\"font-family:Cambria,serif\"><span style=\"color:#000000\"><span style=\"font-weight:400\"><span style=\"font-style:normal\"><span style=\"text-decoration:none\">233<\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/p>\n\t\t\t<\/td>\n\t\t\t<td style=\"border-bottom:1px solid #000000; vertical-align:middle; background-color:#f2f2f2; padding:0px 7px 0px 7px; border-top:1px solid #000000; border-right:1px solid #000000; border-left:1px solid #000000; width:118px\">\n\t\t\t<p style=\"line-height:1.2\"><span style=\"overflow:hidden\"><span style=\"overflow-wrap:break-word\"><span style=\"font-size:9pt; font-variant:normal; white-space:pre-wrap\"><span style=\"font-family:Cambria,serif\"><span style=\"color:#000000\"><span style=\"font-weight:400\"><span style=\"font-style:normal\"><span style=\"text-decoration:none\">Iberdomide (CC-220) Monotherapy or in Combination with an Anti-CD20 Monoclonal Antibody As Effective Therapy in Patients with Relapsed\/Refractory Lymphoma: Early Results from a Phase I\/II Study<\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/p>\n\t\t\t<\/td>\n\t\t\t<td style=\"border-bottom:1px solid #000000; vertical-align:middle; background-color:#f2f2f2; padding:0px 7px 0px 7px; border-top:1px solid #000000; border-right:1px solid #000000; border-left:1px solid #000000; width:84px\">\n\t\t\t<p style=\"line-height:1.2\"><span style=\"overflow:hidden\"><span style=\"overflow-wrap:break-word\"><span style=\"font-size:9pt; font-variant:normal; white-space:pre-wrap\"><span style=\"font-family:Cambria,serif\"><span style=\"color:#000000\"><span style=\"font-weight:400\"><span style=\"font-style:normal\"><span style=\"text-decoration:none\">NCT04464798<\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/p>\n\t\t\t<\/td>\n\t\t\t<td style=\"border-bottom:1px solid #000000; vertical-align:middle; background-color:#f2f2f2; padding:0px 7px 0px 7px; border-top:1px solid #000000; border-right:1px solid #000000; border-left:1px solid #000000; width:94px\">\n\t\t\t<p style=\"line-height:1.2\"><span style=\"overflow:hidden\"><span style=\"overflow-wrap:break-word\"><span style=\"font-size:9pt; font-variant:normal; white-space:pre-wrap\"><span style=\"font-family:Cambria,serif\"><span style=\"color:#000000\"><span style=\"font-weight:400\"><span style=\"font-style:normal\"><span style=\"text-decoration:none\">BMS<\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/p>\n\t\t\t<\/td>\n\t\t\t<td style=\"border-bottom:1px solid #000000; vertical-align:middle; background-color:#f2f2f2; padding:0px 7px 0px 7px; border-top:1px solid #000000; border-right:1px solid #000000; border-left:1px solid #000000; width:111px\">\n\t\t\t<p style=\"line-height:1.2\"><span style=\"overflow:hidden\"><span style=\"overflow-wrap:break-word\"><span style=\"font-size:9pt; font-variant:normal; white-space:pre-wrap\"><span style=\"font-family:Cambria,serif\"><span style=\"color:#000000\"><span style=\"font-weight:400\"><span style=\"font-style:normal\"><span style=\"text-decoration:none\">Immunomodulatory imide drug (IMiDs)<\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/p>\n\t\t\t<\/td>\n\t\t<\/tr>\n\t\t<tr>\n\t\t\t<td style=\"border-bottom:1px solid #000000; vertical-align:middle; background-color:#ffffff; padding:0px 7px 0px 7px; border-top:1px solid #000000; border-right:1px solid #000000; border-left:1px solid #000000; width:96px\">\n\t\t\t<p style=\"line-height:1.2\"><span style=\"overflow:hidden\"><span style=\"overflow-wrap:break-word\"><span style=\"font-size:9pt; font-variant:normal; white-space:pre-wrap\"><span style=\"font-family:Cambria,serif\"><span style=\"color:#000000\"><span style=\"font-weight:700\"><span style=\"font-style:normal\"><span style=\"text-decoration:none\">Tafasitamab + Lenalidomide + R<\/span><\/span><\/span><\/span><\/span><\/span><span style=\"font-size:9pt; font-variant:normal; white-space:pre-wrap\"><span style=\"font-family:'Cambria Math',serif\"><span style=\"color:#000000\"><span style=\"font-weight:700\"><span style=\"font-style:normal\"><span style=\"text-decoration:none\">\u2011<\/span><\/span><\/span><\/span><\/span><\/span><span style=\"font-size:9pt; font-variant:normal; white-space:pre-wrap\"><span style=\"font-family:Cambria,serif\"><span style=\"color:#000000\"><span style=\"font-weight:700\"><span style=\"font-style:normal\"><span style=\"text-decoration:none\">CHOP<\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/p>\n\t\t\t<\/td>\n\t\t\t<td style=\"border-bottom:1px solid #000000; vertical-align:middle; background-color:#ffffff; padding:0px 7px 0px 7px; border-top:1px solid #000000; border-right:1px solid #000000; border-left:1px solid #000000; width:54px\">\n\t\t\t<p style=\"line-height:1.2\"><span style=\"overflow:hidden\"><span style=\"overflow-wrap:break-word\"><span style=\"font-size:9pt; font-variant:normal; white-space:pre-wrap\"><span style=\"font-family:Cambria,serif\"><span style=\"color:#000000\"><span style=\"font-weight:400\"><span style=\"font-style:normal\"><span style=\"text-decoration:none\">1619<\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/p>\n\t\t\t<\/td>\n\t\t\t<td style=\"border-bottom:1px solid #000000; vertical-align:middle; background-color:#ffffff; padding:0px 7px 0px 7px; border-top:1px solid #000000; border-right:1px solid #000000; border-left:1px solid #000000; width:118px\">\n\t\t\t<p style=\"line-height:1.2\"><span style=\"overflow:hidden\"><span style=\"overflow-wrap:break-word\"><span style=\"font-size:9pt; font-variant:normal; white-space:pre-wrap\"><span style=\"font-family:Cambria,serif\"><span style=\"color:#000000\"><span style=\"font-weight:400\"><span style=\"font-style:normal\"><span style=\"text-decoration:none\">First-Mind: Final Analysis from a Phase Ib, Open-Label, Randomized Study to Assess Safety of Tafasitamab or Tafasitamab + Lenalidomide in Addition to R<\/span><\/span><\/span><\/span><\/span><\/span><span style=\"font-size:9pt; font-variant:normal; white-space:pre-wrap\"><span style=\"font-family:'Cambria Math',serif\"><span style=\"color:#000000\"><span style=\"font-weight:400\"><span style=\"font-style:normal\"><span style=\"text-decoration:none\">\u2011<\/span><\/span><\/span><\/span><\/span><\/span><span style=\"font-size:9pt; font-variant:normal; white-space:pre-wrap\"><span style=\"font-family:Cambria,serif\"><span style=\"color:#000000\"><span style=\"font-weight:400\"><span style=\"font-style:normal\"><span style=\"text-decoration:none\">CHOP in Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma<\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/p>\n\t\t\t<\/td>\n\t\t\t<td style=\"border-bottom:1px solid #000000; vertical-align:middle; background-color:#ffffff; padding:0px 7px 0px 7px; border-top:1px solid #000000; border-right:1px solid #000000; border-left:1px solid #000000; width:84px\">\n\t\t\t<p style=\"line-height:1.2\"><span style=\"overflow:hidden\"><span style=\"overflow-wrap:break-word\"><span style=\"font-size:9pt; font-variant:normal; white-space:pre-wrap\"><span style=\"font-family:Cambria,serif\"><span style=\"color:#000000\"><span style=\"font-weight:400\"><span style=\"font-style:normal\"><span style=\"text-decoration:none\">NCT04134936<\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/p>\n\n\t\t\t<p style=\"line-height:1.2\"><span style=\"overflow:hidden\"><span style=\"overflow-wrap:break-word\"><span style=\"font-size:9pt; font-variant:normal; white-space:pre-wrap\"><span style=\"font-family:Cambria,serif\"><span style=\"color:#000000\"><span style=\"font-weight:400\"><span style=\"font-style:normal\"><span style=\"text-decoration:none\">(First-MIND)<\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/p>\n\t\t\t<\/td>\n\t\t\t<td style=\"border-bottom:1px solid #000000; vertical-align:middle; background-color:#ffffff; padding:0px 7px 0px 7px; border-top:1px solid #000000; border-right:1px solid #000000; border-left:1px solid #000000; width:94px\">\n\t\t\t<p style=\"line-height:1.2\"><span style=\"overflow:hidden\"><span style=\"overflow-wrap:break-word\"><span style=\"font-size:9pt; font-variant:normal; white-space:pre-wrap\"><span style=\"font-family:Cambria,serif\"><span style=\"color:#000000\"><span style=\"font-weight:400\"><span style=\"font-style:normal\"><span style=\"text-decoration:none\">MorphoSys AG<\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/p>\n\t\t\t<\/td>\n\t\t\t<td style=\"border-bottom:1px solid #000000; vertical-align:middle; background-color:#ffffff; padding:0px 7px 0px 7px; border-top:1px solid #000000; border-right:1px solid #000000; border-left:1px solid #000000; width:111px\">\n\t\t\t<p style=\"line-height:1.2\"><span style=\"overflow:hidden\"><span style=\"overflow-wrap:break-word\"><span style=\"font-size:9pt; font-variant:normal; white-space:pre-wrap\"><span style=\"font-family:Cambria,serif\"><span style=\"color:#000000\"><span style=\"font-weight:400\"><span style=\"font-style:normal\"><span style=\"text-decoration:none\">CD19-directed monoclonal antibody<\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/p>\n\t\t\t<\/td>\n\t\t<\/tr>\n\t\t<tr>\n\t\t\t<td style=\"border-bottom:1px solid #000000; vertical-align:middle; background-color:#f2f2f2; padding:0px 7px 0px 7px; border-top:1px solid #000000; border-right:1px solid #000000; border-left:1px solid #000000; width:96px\">\n\t\t\t<p style=\"line-height:1.2\"><span style=\"overflow:hidden\"><span style=\"overflow-wrap:break-word\"><span style=\"font-size:9pt; font-variant:normal; white-space:pre-wrap\"><span style=\"font-family:Cambria,serif\"><span style=\"color:#000000\"><span style=\"font-weight:700\"><span style=\"font-style:normal\"><span style=\"text-decoration:none\">Glofitamab + R-CHOP<\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/p>\n\t\t\t<\/td>\n\t\t\t<td style=\"border-bottom:1px solid #000000; vertical-align:middle; background-color:#f2f2f2; padding:0px 7px 0px 7px; border-top:1px solid #000000; border-right:1px solid #000000; border-left:1px solid #000000; width:54px\">\n\t\t\t<p style=\"line-height:1.2\"><span style=\"overflow:hidden\"><span style=\"overflow-wrap:break-word\"><span style=\"font-size:9pt; font-variant:normal; white-space:pre-wrap\"><span style=\"font-family:Cambria,serif\"><span style=\"color:#000000\"><span style=\"font-weight:400\"><span style=\"font-style:normal\"><span style=\"text-decoration:none\">737<\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/p>\n\t\t\t<\/td>\n\t\t\t<td style=\"border-bottom:1px solid #000000; vertical-align:middle; background-color:#f2f2f2; padding:0px 7px 0px 7px; border-top:1px solid #000000; border-right:1px solid #000000; border-left:1px solid #000000; width:118px\">\n\t\t\t<p style=\"line-height:1.2\"><span style=\"overflow:hidden\"><span style=\"overflow-wrap:break-word\"><span style=\"font-size:9pt; font-variant:normal; white-space:pre-wrap\"><span style=\"font-family:Cambria,serif\"><span style=\"color:#000000\"><span style=\"font-weight:400\"><span style=\"font-style:normal\"><span style=\"text-decoration:none\">Glofitamab Plus R-CHOP Induces High Response Rates and a Favorable Safety Profile in Patients with Previously Untreated Diffuse Large B-Cell Lymphoma (DLBCL): Results from a Phase Ib Study<\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/p>\n\t\t\t<\/td>\n\t\t\t<td style=\"border-bottom:1px solid #000000; vertical-align:middle; background-color:#f2f2f2; padding:0px 7px 0px 7px; border-top:1px solid #000000; border-right:1px solid #000000; border-left:1px solid #000000; width:84px\">\n\t\t\t<p style=\"line-height:1.2\"><span style=\"overflow:hidden\"><span style=\"overflow-wrap:break-word\"><span style=\"font-size:9pt; font-variant:normal; white-space:pre-wrap\"><span style=\"font-family:Cambria,serif\"><span style=\"color:#000000\"><span style=\"font-weight:400\"><span style=\"font-style:normal\"><span style=\"text-decoration:none\">NCT03467373<\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/p>\n\t\t\t<\/td>\n\t\t\t<td style=\"border-bottom:1px solid #000000; vertical-align:middle; background-color:#f2f2f2; padding:0px 7px 0px 7px; border-top:1px solid #000000; border-right:1px solid #000000; border-left:1px solid #000000; width:94px\">\n\t\t\t<p style=\"line-height:1.2\"><span style=\"overflow:hidden\"><span style=\"overflow-wrap:break-word\"><span style=\"font-size:9pt; font-variant:normal; white-space:pre-wrap\"><span style=\"font-family:Cambria,serif\"><span style=\"color:#000000\"><span style=\"font-weight:400\"><span style=\"font-style:normal\"><span style=\"text-decoration:none\">Roche<\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/p>\n\t\t\t<\/td>\n\t\t\t<td style=\"border-bottom:1px solid #000000; vertical-align:middle; background-color:#f2f2f2; padding:0px 7px 0px 7px; border-top:1px solid #000000; border-right:1px solid #000000; border-left:1px solid #000000; width:111px\">\n\t\t\t<p style=\"line-height:1.2\"><span style=\"overflow:hidden\"><span style=\"overflow-wrap:break-word\"><span style=\"font-size:9pt; font-variant:normal; white-space:pre-wrap\"><span style=\"font-family:Cambria,serif\"><span style=\"color:#000000\"><span style=\"font-weight:400\"><span style=\"font-style:normal\"><span style=\"text-decoration:none\">Bispecific antibody<\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/p>\n\t\t\t<\/td>\n\t\t<\/tr>\n\t\t<tr>\n\t\t\t<td style=\"border-bottom:1px solid #000000; vertical-align:middle; background-color:#ffffff; padding:0px 7px 0px 7px; border-top:1px solid #000000; border-right:1px solid #000000; border-left:1px solid #000000; width:96px\">\n\t\t\t<p style=\"line-height:1.2\"><span style=\"overflow:hidden\"><span style=\"overflow-wrap:break-word\"><span style=\"font-size:9pt; font-variant:normal; white-space:pre-wrap\"><span style=\"font-family:Cambria,serif\"><span style=\"color:#000000\"><span style=\"font-weight:700\"><span style=\"font-style:normal\"><span style=\"text-decoration:none\">YTB323<\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/p>\n\t\t\t<\/td>\n\t\t\t<td style=\"border-bottom:1px solid #000000; vertical-align:middle; background-color:#ffffff; padding:0px 7px 0px 7px; border-top:1px solid #000000; border-right:1px solid #000000; border-left:1px solid #000000; width:54px\">\n\t\t\t<p style=\"line-height:1.2\"><span style=\"overflow:hidden\"><span style=\"overflow-wrap:break-word\"><span style=\"font-size:9pt; font-variant:normal; white-space:pre-wrap\"><span style=\"font-family:Cambria,serif\"><span style=\"color:#000000\"><span style=\"font-weight:400\"><span style=\"font-style:normal\"><span style=\"text-decoration:none\">439<\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/p>\n\t\t\t<\/td>\n\t\t\t<td style=\"border-bottom:1px solid #000000; vertical-align:middle; background-color:#ffffff; padding:0px 7px 0px 7px; border-top:1px solid #000000; border-right:1px solid #000000; border-left:1px solid #000000; width:118px\">\n\t\t\t<p style=\"line-height:1.2\"><span style=\"overflow:hidden\"><span style=\"overflow-wrap:break-word\"><span style=\"font-size:9pt; font-variant:normal; white-space:pre-wrap\"><span style=\"font-family:Cambria,serif\"><span style=\"color:#000000\"><span style=\"font-weight:400\"><span style=\"font-style:normal\"><span style=\"text-decoration:none\">YTB323 (Rapcabtagene Autoleucel) Demonstrates Durable Efficacy and a Manageable Safety Profile in Patients with Relapsed\/Refractory Diffuse Large B-Cell Lymphoma: Phase I Study Update<\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/p>\n\t\t\t<\/td>\n\t\t\t<td style=\"border-bottom:1px solid #000000; vertical-align:middle; background-color:#ffffff; padding:0px 7px 0px 7px; border-top:1px solid #000000; border-right:1px solid #000000; border-left:1px solid #000000; width:84px\">\n\t\t\t<p style=\"line-height:1.2\"><span style=\"overflow:hidden\"><span style=\"overflow-wrap:break-word\"><span style=\"font-size:9pt; font-variant:normal; white-space:pre-wrap\"><span style=\"font-family:Cambria,serif\"><span style=\"color:#000000\"><span style=\"font-weight:400\"><span style=\"font-style:normal\"><span style=\"text-decoration:none\">NCT03960840<\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/p>\n\t\t\t<\/td>\n\t\t\t<td style=\"border-bottom:1px solid #000000; vertical-align:middle; background-color:#ffffff; padding:0px 7px 0px 7px; border-top:1px solid #000000; border-right:1px solid #000000; border-left:1px solid #000000; width:94px\">\n\t\t\t<p style=\"line-height:1.2\"><span style=\"overflow:hidden\"><span style=\"overflow-wrap:break-word\"><span style=\"font-size:9pt; font-variant:normal; white-space:pre-wrap\"><span style=\"font-family:Cambria,serif\"><span style=\"color:#000000\"><span style=\"font-weight:400\"><span style=\"font-style:normal\"><span style=\"text-decoration:none\">Novartis Pharmaceuticals<\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/p>\n\t\t\t<\/td>\n\t\t\t<td style=\"border-bottom:1px solid #000000; vertical-align:middle; background-color:#ffffff; padding:0px 7px 0px 7px; border-top:1px solid #000000; border-right:1px solid #000000; border-left:1px solid #000000; width:111px\">\n\t\t\t<p style=\"line-height:1.2\"><span style=\"overflow:hidden\"><span style=\"overflow-wrap:break-word\"><span style=\"font-size:9pt; font-variant:normal; white-space:pre-wrap\"><span style=\"font-family:Cambria,serif\"><span style=\"color:#000000\"><span style=\"font-weight:400\"><span style=\"font-style:normal\"><span style=\"text-decoration:none\">CAR-T cell therapy<\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/p>\n\t\t\t<\/td>\n\t\t<\/tr>\n\t<\/tbody>\n<\/table>\n<\/div>\n\n\n\n<div style=\"height:20px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<figure class=\"wp-block-image size-large is-resized\"><a href=\"pipeline-insighthttps:\/\/www.delveinsight.com\/report-store\/diffuse-large-b-cell-lymphoma-pipeline-insight\"><img decoding=\"async\" src=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/04\/17160005\/Diffuse-Large-B-Cell-Lymphoma-Pipeline-Insight-and-analysis-1024x256.png\" alt=\"Diffuse Large B-Cell Lymphoma (DLBCL) Pipeline Insight and Analysis\" class=\"wp-image-22287\" width=\"1024\" height=\"256\" srcset=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/04\/17160005\/Diffuse-Large-B-Cell-Lymphoma-Pipeline-Insight-and-analysis-1024x256.png 1024w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/04\/17160005\/Diffuse-Large-B-Cell-Lymphoma-Pipeline-Insight-and-analysis-300x75.png 300w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/04\/17160005\/Diffuse-Large-B-Cell-Lymphoma-Pipeline-Insight-and-analysis-150x38.png 150w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/04\/17160005\/Diffuse-Large-B-Cell-Lymphoma-Pipeline-Insight-and-analysis-768x192.png 768w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/04\/17160005\/Diffuse-Large-B-Cell-Lymphoma-Pipeline-Insight-and-analysis-1536x384.png 1536w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/04\/17160005\/Diffuse-Large-B-Cell-Lymphoma-Pipeline-Insight-and-analysis-1568x392.png 1568w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/04\/17160005\/Diffuse-Large-B-Cell-Lymphoma-Pipeline-Insight-and-analysis.png 1584w\" sizes=\"(max-width: 1024px) 100vw, 1024px\" \/><\/a><\/figure>\n","protected":false},"excerpt":{"rendered":"<p>Blood cancers have seen tremendous advancements in the past few years owing to the dedication of the researchers who are putting their endless efforts just to bring innovation into the lives of suffering patients. These experiments and their upshots are always brought to us through various platforms, the American Society of Hematology (ASH) being one [&hellip;]<\/p>\n","protected":false},"author":6,"featured_media":20096,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_editorskit_title_hidden":false,"_editorskit_reading_time":2,"_editorskit_is_block_options_detached":false,"_editorskit_block_options_position":"{}","advgb_blocks_editor_width":"","advgb_blocks_columns_visual_guide":"","footnotes":""},"categories":[41],"tags":[20004,20005,20006,18917,20012,20014,20013,20007,20008,18921,20009,20010,20011,20015,706],"industry":[17225],"therapeutic_areas":[17233,17228],"class_list":["post-20090","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-snippets","tag-american-society-of-hematology","tag-american-society-of-hematology-ash","tag-american-society-of-hematology-2022","tag-ash","tag-ash-2022","tag-ash-2022-abstracts","tag-ash-annual-meeting","tag-healthcare-conferences","tag-healthcare-conferences-2022","tag-hematology","tag-medical-conferences","tag-medical-conferences-2022","tag-pharmaceutical-conferences","tag-pharmaceutical-conferences-2022","tag-pharmaceutical-industry","industry-pharmaceutical","therapeutic_areas-hematological-disorders","therapeutic_areas-oncology"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v25.8 (Yoast SEO v25.8) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>ASH Annual Meeting 2022 | DLBCL Abstracts, Breakthroughs, and News<\/title>\n<meta name=\"description\" content=\"Globally, several pharma companies are set to present key DLBCL abstracts at the 64th American Society of Hematology (ASH) Annual Meeting\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.delveinsight.com\/blog\/ash-annual-meeting-dlbcl-abstracts-and-breakthroughs\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"ASH Annual Meeting 2022 | DLBCL Abstracts, Breakthroughs, and News\" \/>\n<meta property=\"og:description\" content=\"Globally, several pharma companies are set to present key DLBCL abstracts at the 64th American Society of Hematology (ASH) Annual Meeting\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.delveinsight.com\/blog\/ash-annual-meeting-dlbcl-abstracts-and-breakthroughs\" \/>\n<meta property=\"og:site_name\" content=\"DelveInsight Business Research\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/\" \/>\n<meta property=\"article:published_time\" content=\"2022-12-09T09:39:43+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2023-04-17T11:20:42+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/12\/09150520\/ASH-Annual-Meeting-Major-Abstracts-Breakthroughs-Updates-and-News.png\" \/>\n\t<meta property=\"og:image:width\" content=\"772\" \/>\n\t<meta property=\"og:image:height\" content=\"482\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"DelveInsight\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:site\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"DelveInsight\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"ASH Annual Meeting 2022 | DLBCL Abstracts, Breakthroughs, and News","description":"Globally, several pharma companies are set to present key DLBCL abstracts at the 64th American Society of Hematology (ASH) Annual Meeting","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.delveinsight.com\/blog\/ash-annual-meeting-dlbcl-abstracts-and-breakthroughs","og_locale":"en_US","og_type":"article","og_title":"ASH Annual Meeting 2022 | DLBCL Abstracts, Breakthroughs, and News","og_description":"Globally, several pharma companies are set to present key DLBCL abstracts at the 64th American Society of Hematology (ASH) Annual Meeting","og_url":"https:\/\/www.delveinsight.com\/blog\/ash-annual-meeting-dlbcl-abstracts-and-breakthroughs","og_site_name":"DelveInsight Business Research","article_publisher":"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/","article_published_time":"2022-12-09T09:39:43+00:00","article_modified_time":"2023-04-17T11:20:42+00:00","og_image":[{"width":772,"height":482,"url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/12\/09150520\/ASH-Annual-Meeting-Major-Abstracts-Breakthroughs-Updates-and-News.png","type":"image\/png"}],"author":"DelveInsight","twitter_card":"summary_large_image","twitter_creator":"@DelveInsight","twitter_site":"@DelveInsight","twitter_misc":{"Written by":"DelveInsight","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.delveinsight.com\/blog\/ash-annual-meeting-dlbcl-abstracts-and-breakthroughs","url":"https:\/\/www.delveinsight.com\/blog\/ash-annual-meeting-dlbcl-abstracts-and-breakthroughs","name":"ASH Annual Meeting 2022 | DLBCL Abstracts, Breakthroughs, and News","isPartOf":{"@id":"https:\/\/www.delveinsight.com\/blog\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.delveinsight.com\/blog\/ash-annual-meeting-dlbcl-abstracts-and-breakthroughs#primaryimage"},"image":{"@id":"https:\/\/www.delveinsight.com\/blog\/ash-annual-meeting-dlbcl-abstracts-and-breakthroughs#primaryimage"},"thumbnailUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/12\/09150520\/ASH-Annual-Meeting-Major-Abstracts-Breakthroughs-Updates-and-News.png","datePublished":"2022-12-09T09:39:43+00:00","dateModified":"2023-04-17T11:20:42+00:00","author":{"@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/0d96a31a370c143ffdb481d985d7edfd"},"description":"Globally, several pharma companies are set to present key DLBCL abstracts at the 64th American Society of Hematology (ASH) Annual Meeting","inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.delveinsight.com\/blog\/ash-annual-meeting-dlbcl-abstracts-and-breakthroughs"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/ash-annual-meeting-dlbcl-abstracts-and-breakthroughs#primaryimage","url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/12\/09150520\/ASH-Annual-Meeting-Major-Abstracts-Breakthroughs-Updates-and-News.png","contentUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/12\/09150520\/ASH-Annual-Meeting-Major-Abstracts-Breakthroughs-Updates-and-News.png","width":772,"height":482,"caption":"ASH Annual Meeting, Major Abstracts, Breakthroughs, Updates, and News"},{"@type":"WebSite","@id":"https:\/\/www.delveinsight.com\/blog\/#website","url":"https:\/\/www.delveinsight.com\/blog\/","name":"DelveInsight Business Research","description":"Blog","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.delveinsight.com\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/0d96a31a370c143ffdb481d985d7edfd","name":"DelveInsight","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/f9314f22b8c5b61d496451e91f32488d2457ecb59283b7b2ad7e82d330b47aba?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/f9314f22b8c5b61d496451e91f32488d2457ecb59283b7b2ad7e82d330b47aba?s=96&d=mm&r=g","caption":"DelveInsight"}}]}},"author_meta":{"display_name":"DelveInsight","author_link":"https:\/\/www.delveinsight.com\/blog\/author\/arawat"},"featured_img":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/12\/09150520\/ASH-Annual-Meeting-Major-Abstracts-Breakthroughs-Updates-and-News-300x187.png","coauthors":[],"tax_additional":{"categories":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/snippets\/\" class=\"advgb-post-tax-term\">Snippets - A Small piece of News or Article<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Snippets - A Small piece of News or Article<\/span>"]},"tags":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/snippets\/\" class=\"advgb-post-tax-term\">American Society of Hematology<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/snippets\/\" class=\"advgb-post-tax-term\">American Society of Hematology (ASH)<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/snippets\/\" class=\"advgb-post-tax-term\">American Society of Hematology 2022<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/snippets\/\" class=\"advgb-post-tax-term\">ASH<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/snippets\/\" class=\"advgb-post-tax-term\">ASH 2022<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/snippets\/\" class=\"advgb-post-tax-term\">ASH 2022 Abstracts<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/snippets\/\" class=\"advgb-post-tax-term\">ASH Annual Meeting<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/snippets\/\" class=\"advgb-post-tax-term\">Healthcare Conferences<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/snippets\/\" class=\"advgb-post-tax-term\">Healthcare Conferences 2022<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/snippets\/\" class=\"advgb-post-tax-term\">Hematology<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/snippets\/\" class=\"advgb-post-tax-term\">Medical Conferences<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/snippets\/\" class=\"advgb-post-tax-term\">Medical Conferences 2022<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/snippets\/\" class=\"advgb-post-tax-term\">Pharmaceutical Conferences<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/snippets\/\" class=\"advgb-post-tax-term\">Pharmaceutical Conferences 2022<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/snippets\/\" class=\"advgb-post-tax-term\">Pharmaceutical Industry<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">American Society of Hematology<\/span>","<span class=\"advgb-post-tax-term\">American Society of Hematology (ASH)<\/span>","<span class=\"advgb-post-tax-term\">American Society of Hematology 2022<\/span>","<span class=\"advgb-post-tax-term\">ASH<\/span>","<span class=\"advgb-post-tax-term\">ASH 2022<\/span>","<span class=\"advgb-post-tax-term\">ASH 2022 Abstracts<\/span>","<span class=\"advgb-post-tax-term\">ASH Annual Meeting<\/span>","<span class=\"advgb-post-tax-term\">Healthcare Conferences<\/span>","<span class=\"advgb-post-tax-term\">Healthcare Conferences 2022<\/span>","<span class=\"advgb-post-tax-term\">Hematology<\/span>","<span class=\"advgb-post-tax-term\">Medical Conferences<\/span>","<span class=\"advgb-post-tax-term\">Medical Conferences 2022<\/span>","<span class=\"advgb-post-tax-term\">Pharmaceutical Conferences<\/span>","<span class=\"advgb-post-tax-term\">Pharmaceutical Conferences 2022<\/span>","<span class=\"advgb-post-tax-term\">Pharmaceutical Industry<\/span>"]}},"comment_count":"0","relative_dates":{"created":"Posted 3 years ago","modified":"Updated 3 years ago"},"absolute_dates":{"created":"Posted on Dec 9, 2022","modified":"Updated on Apr 17, 2023"},"absolute_dates_time":{"created":"Posted on Dec 9, 2022 3:09 pm","modified":"Updated on Apr 17, 2023 4:50 pm"},"featured_img_caption":"ASH Annual Meeting, Major Abstracts, Breakthroughs, Updates, and News","series_order":"","_links":{"self":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/20090","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/users\/6"}],"replies":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/comments?post=20090"}],"version-history":[{"count":0,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/20090\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media\/20096"}],"wp:attachment":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media?parent=20090"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/categories?post=20090"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/tags?post=20090"},{"taxonomy":"industry","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/industry?post=20090"},{"taxonomy":"therapeutic_areas","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/therapeutic_areas?post=20090"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}